RSS Feeds

Email a Friend Printer Friendly

How DDT metabolite disrupts breast cancer cells

February 14, 2008

Research has shown that the main metabolite of the insecticide DDT could be associated with aggressive breast cancer tumours, but there has been no explanation for this observation to date. Now a report published in the open access journal Breast Cancer Research shows how DDT could act to disrupt hormone-sensitive breast cancer cells.

Michel Aube and colleagues from Universite Laval and Institut national de sante publique in Quebec, Canada have published findings suggesting that DDT¡'s main metabolite, 1,1-dichloro-2,2-bis(p-chlorophenyl)ethylene (p,pi'-DDE), could increase breast cancer progression. They suggest a mechanism whereby p,p¡'-DDE opposes the androgen signalling pathway that inhibits growth in hormone-responsive breast cancer cells.

The team tested the effect of p,p¡'-DDE on the proliferation of CAMA-1 cells, a human breast cancer cell line that expresses the estrogen receptor alpha (ERa) and the androgen receptor (AR), either with or without physiological concentrations of estrogens and androgens. They also assessed p,p¡'-DDE-induced modifications in cell cycle entry and the expression of sex-steroid dependent genes including ESR1 and CCND1, the latter coding for a key protein involved in cell proliferation.

When estrogens and androgens were present in the cell culture medium, increasing concentrations of p,p¡'-DDE accelerated the growth of CAMA-1 breast cancer cells. p,p¡'-DDE had a similar effect on the proliferation of MCF7-AR1 cells, an estrogen responsive cell line genetically engineered to over express the AR. Adding the potent androgen dihydrotestosterone together with estradiol to the cell culture medium decreased the recruitment of CAMA-1 cells in the S phase and the expression of ESR1 and CCND1, by comparison with cells treated with estradiol alone. These androgen-mediated effects were blocked with similar efficacy by p,p¡'-DDE and the potent antiandrogen hydroxyflutamide.

'Our results suggest that in addition to estrogenic compounds, which have been the main focus of researchers over the past decades, chemicals that block the AR could favour breast cancer progression' says Pierre Ayotte, who is leading the research team.

Ayotte's team had previously linked concentrations of p,p¡'-DDE with tumour aggressiveness in women with breast cancer. They are now investigating the effect on breast cancer cell proliferation of a complex mixture of environmental chemicals, similar to that found in the blood of women, which comprises compounds with estrogenic and antiandrogenic activities.

BioMed Central